Description
This active molecular is an AMPA receptor antagonist which blocks AMPA receptors in 10-20µM concentrations. It is also a Glutamate receptor antagonist. NBQX was found to have anticonvulsant activity in rodent seizure models. This compound has neuroprotective properties. In Nov 1995, NBQX was discontinued preclinical for Stroke in Denmark and in United Kingdom. In Nov 1997, NBQX was discontinued preclinical for Parkinson's disease in USA